Beyond Weight Loss: How GLP-1 Agonists Influence Gut Bioenergetics and the Host Capacity Model — What This Does Not Prove

The mechanistic alignment described here is consistent with current research but should not be over-read. The Molecular Metabolism work is a germ-free mouse model and not a direct demonstration of the same mechanism in human chronic illness. The skeletal muscle data does not generalize automatically to colonic epithelium. The microbiome literature on GLP-1 agonists is still developing and the effects are heterogeneous between individuals. None of this work establishes that GLP-1 agonists treat, reverse, or cure SIBO, MCAS, long COVID, or any other chronic condition. The framing here is mechanistic interpretation, not a treatment recommendation.